Cazzola, M., Calzetta, L., Rogliani, P., Page, C., & Matera, M. G. (2018). Impact of doxofylline in COPD: A pair-wise meta-analysis. *PULMONARY PHARMACOLOGY AND THERAPEUTICS, 51.*
https://doi.org/10.1016/j.pupt.2018.04.010
Impact of doxofylline in COPD: A pairwise meta-analysis

Mario Cazzola\textsuperscript{a}, Luigino Calzetta\textsuperscript{a,\textast}, Paola Rogliani\textsuperscript{a}, Clive Page\textsuperscript{b}, Maria Gabriella Matera\textsuperscript{c}

\textsuperscript{a} Unit of Respiratory Medicine, Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy
\textsuperscript{b} Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK
\textsuperscript{c} Unit of Pharmacology, Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy

\textbf{Abstract}

Doxofylline is an effective bronchodilator for relieving airway obstruction in patients with asthma or chronic obstructive pulmonary disease (COPD), and displays a better safety profile with respect to theophylline. Herein, we performed a pairwise meta-analysis of the currently available data to provide consistent and homogeneous findings on the impact of this xanthine in COPD patients. Results obtained from 820 patients were selected from 20 clinical trials. Meta-regression was performed to examine the source of heterogeneity between-studies and identify potential confounder covariates. The quality of the evidence was assessed by the GRADE system. Doxofylline induced a significant (P < 0.001) increase in forced expiratory volume in 1 s (FEV\textsubscript{1}) of 8.20% (95\%CI 4.00–12.41; I\textsuperscript{2} 93\%) and 317 ml (95\%CI 19–439; I\textsuperscript{2} 87\%) compared with baseline. The total administered dose of doxofylline significantly (P < 0.001) interacted with the size of the effect estimates detected for FEV\textsubscript{1}. Doxofylline induced a significant (P < 0.001), although moderate, increase in adverse events (AEs) frequency (proportion 0.03, 95\%CI 0.02–0.04; I\textsuperscript{2} 88\%), but only epigastralgia, nausea, dyspepsia and headache were statistically significant (P < 0.05). The GRADE analysis indicated high quality of evidence (+ + + +) for the impact of doxofylline on FEV\textsubscript{1}, and moderate quality of evidence (+ + +) for the safety profile in COPD patients. Doxofylline is an effective and safe medicine when administered to patients with COPD and can be considered as an alternative to theophylline.

1. Introduction

Doxofylline is a xanthine that is structurally different from theophylline by having a dioxalane group at position 7 of the xanthine ring \cite{1}. Consequently, it has mechanisms of action distinct from those of theophylline \cite{2,3,4} in that lacks adenosine receptor antagonism or the ability to inhibit any of the known PDE isoforms, which may contribute to the better safety profile. Furthermore, unlike theophylline, doxofylline does not interact with histone deacetylases \cite{3}, but is able to positively interact with β\textsubscript{2}-adrenoceptors \cite{5}.

The narrative analysis of literature has suggested that doxofylline is an effective bronchodilator for relieving airway obstruction in patients with asthma or chronic obstructive pulmonary disease (COPD) and displays a better safety profile with respect to theophylline, having a favourable risk-to-benefit ratio \cite{2,4,6}. Unfortunately, narrative reviews primarily focused on the conclusions reached in various studies \cite{7} and, furthermore, mainly related with the researchers’ personal preference. Therefore, in evaluating this type of research, one needs to examine how the critical analysis was done, ensuring the rigor in the methodology and the review process, and checking for possible bias stemming from the researchers’ choices surrounding the development of the research aim/question, the selection of articles to review, and the transparency in their process or lack of it \cite{8}.

Meta-analysis, which is an analytical technique designed to summarize the results of multiple studies, represents a powerful way to effectively increase sample size to provide a more valid pooled estimate \cite{9}. Meta-analysis can be considered as a systematic study of all studies that have been conducted to answer a specific question or hypothesis \cite{10}. Actually, the meta-analytic approach usually has four main goals: (1) to evaluate the consistency/variability of the results between the primary studies included in the review (i.e., the between-study heterogeneity); (2) to investigate and explain (if feasible) the causes of any observed heterogeneity (e.g., through subgroup or meta-regression analyses) to improve scientific understanding; (3) to calculate a

\begin{thebibliography}{9}
\bibitem{1} Calzetta, L. Corresponding author. Department of Experimental Medicine and Surgery, University of Rome “Tor Vergata”, Via Montpellier 1, 00133, Rome, Italy.
\textit{E-mail address:} luigino.calzetta@uniroma2.it (L. Calzetta).
\textit{doi:10.1016/j.pupt.2018.04.010}
\textit{Available online 26 April 2018}
\textit{1094-5539/ © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).}
\end{thebibliography}
summary effect size along with a confidence interval; and (4) to assess the robustness of the cumulative effect size through sensitivity analyses and formal evaluations of the potential sources of study bias, including publication bias, that stem from the primary studies and might have an impact on the calculated summary effect [8].

We have therefore investigated the use of doxofylline in the treatment of patients with COPD patients using a pairwise meta-analysis of the currently available data in order to provide consistent and homogeneous findings.

2. Materials and methods

2.1. Search strategy

This pairwise meta-analysis has been registered in PROSPERO (registration number: CRD42017077901; available at https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=77901), and performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement (Figure S1) [11]. This quantitative synthesis satisfied all the recommended items reported by the PRISMA-P 2015 checklist [12].

We undertook a comprehensive literature search for published and unpublished clinical trials (both randomized and non-randomized) evaluating the influence of doxofylline in COPD patients. Observational studies were not included in this meta-analysis. The terms “doxofylline” and their synonyms (doxophylline, doxofilline, doxofilina) were searched for the drug, and the terms “chronic obstructive pulmonary disease” OR “COPD” were searched for the disease. The search was performed in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Scopus, Google Scholar, Web of Science and ClinicalTrials.gov databases through September 2017, in order to provide for relevant studies available up to September 20, 2017. Studies reporting the impact of doxofylline vs. control (placebo, untreated subjects, baseline values) on lung function and safety in COPD patients were included in this meta-analysis.

Two reviewers independently checked the relevant studies identified from literature searches and databases. The studies were selected in agreement with the previously mentioned criteria, and any difference in opinion about eligibility was resolved by consensus.

2.2. Quality score, risk of bias and evidence profile

The Jadad score, with a scale of 1–5 (score of 5 being the best quality), was used to assess the quality of the studies concerning the likelihood of biases related to randomization, double blinding, withdrawals and dropouts [13]. A Jadad score ≥ 3 was defined to identify high-quality studies. Two reviewers independently assessed the quality of individual studies, and any difference in opinion about the quality score was resolved by consensus.

The risk of publication bias was assessed by applying the funnel plot and Egger's test through the following regression equation: $\text{SND} = a + b \times \text{precision}$, where SND represents the standard normal deviation (treatment effect divided by its standard error [SE]), and precision represents the reciprocal of the standard error. Evidence of asymmetry from Egger's test was considered to be significant at $P < 0.1$, and the graphical representation of 90% confidence bands are presented [13].

Meta-regression analysis was performed to examine the source of heterogeneity between-studies and identify potential confounder covariates specifically for the primary endpoints [14].

The quality of the evidence obtained for the primary endpoints was assessed in agreement with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system [15].

2.3. Data extraction

Data from included studies were extracted and checked for study characteristics and duration, doses of doxofylline, concomitant medications, disease characteristics, ethnicity, age, gender, lung function, safety, and Jadad score.

2.4. End points

The primary endpoints of this meta-analysis were the impact of doxofylline vs. control in terms of changes in forced expiratory volume in 1 s (FEV1) and frequency of adverse events (AEs). The reported length of follow-up could not be the same across clinical trials. Considering that the probability of detecting an AE is proportional to the duration of treatment, in this meta-analysis data on AEs have been normalized as a function of events per person-time (namely person-week), in which the numerator represents the count of total AEs and the denominator represents the given time duration multiplied by the number of patients [16,17].

The secondary endpoints were the therapeutic efficacy (the rate of patients that achieved the 3rd or 4th rank in a four-point non-validated scale, or that achieved the 2nd or 3rd rank in a three-point non-validated scale, where the higher values represented greater therapeutic efficacy [18-22]), the daily use or rescue medication (short-acting β2-agonists), and the assessment of dyspnea via Medical Research Council (MRC) scale [23], or a non-validated dyspnea score that assessed dyspnea with a 4-point scale [24,25]. More details concerning the scales used to assess the therapeutic efficacy and dyspnea are reported in the supplementary data file (Table S1).

2.5. Data analysis

Results are expressed as Standardized Mean Difference (SMD), Mean Difference (MD), Proportion (Pr), Logarithmic transformed Proportion (Log Proportion, PLN), and 95% confidence interval (95%CI). The overall changes in FEV1 are reported as SMD (SMD = [difference in mean outcome between groups] $\times$ [standard deviation of outcome among participants]) [11], since this outcome was not always described in a standard manner across the studies (sometimes expressed as % predicted instead of volume [L or ml]). SMD has also been re-expressed in agreement with the rules of thumb proposed by Cohen and The Cochrane Collaboration* [17,26]. Specifically < 0.5 represents a small effect, 0.5 to 0.8 a moderate effect, 0.8 to 1.3 a large effect, and > 1.3 a very large effect. The subset analyses of the changes in FEV1 specifically expressed as % or volume (L or ml) are reported as MD. The frequency of AEs and the therapeutic efficacy are reported as Pr since most studies (85%) compared doxofylline vs. active comparators and not vs. placebo. Data on symptoms (dyspnea scores) are reported as MD and the use of rescue medication as PLN.

Since data were selected from a series of studies performed by researchers operating independently, and a common effect size cannot be assumed, we used the random-effects model in order to balance the study weights and to adequately estimate the 95%CI of the mean distribution of drugs effect on the investigated variables [27].

Subset analyses were performed with regard to the quality of studies (Jadad score ≥ 3), the units by which FEV1 was reported in the studies (% predicted, volume [L or ml]), and specific AEs.

A pooled analysis was performed to calculate the frequency of AEs, ranked in agreement with the “European Medicine Agency, section 4.8: Undesirable effects”, as follows: very common ≥1/10, common ≥1/100 to < 1/10, uncommon ≥1/1000 to < 1/100, frequency not known if not calculable from the available data (http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2013/01/WC500137021.pdf).

OpenMetaAnalyst [28] software was used for performing the meta-analysis and meta-regression, GraphPad Prism (CA, US) software to graph the data, and GRADEPro to assess the quality of evidence [15]. The statistical significance was assessed for $P < 0.05$, and moderate to high levels of heterogeneity were considered for $I^2 > 50%$. 
3. Results

3.1. Studies characteristics

Results obtained from 820 COPD patients were selected from 20 studies [18–25,29–40] published between 1988 and 2016. The relevant studies and patients characteristics are described in Table S2. All studies were full-text papers but two that were congress abstracts [35,37]. Five studies had a Jadad score ≥ 3 [18,19,23,34,40], thirteen studies had a Jadad score ≥ 1 and < 3 [20–22,24,25,29–33,36,38,39], whereas for two studies it was not possible to calculate Jadad score [35,37]. The period of treatment ranged from one day to 52 weeks.

3.2. Quantitative synthesis

3.2.1. Primary endpoints

Doxofylline elicited a beneficial impact on the primary endpoints of this meta-analysis. The treatment with doxofylline significantly (P < 0.001) increased FEV1 compared to control (SMD 1.14, 95%CI 0.79–1.49; I² 88%). Specifically, doxofylline induced a large to very large improvement in FEV1, in agreement with the rules of thumb for the interpretation of effect sizes on the basis of SMDs (Fig. 1) [17,26].

The subset analysis performed by assessing exclusively randomized clinical trials (RCTs) indicated that doxofylline induced a significant (P < 0.001) increase in FEV1 of 8.20% (95%CI 4.00–12.41; I² 93%) and 324 ml (95%CI 161–487; I² 91%), compared to baseline (Fig. 2A and B). A further subset analysis carried out considering exclusively the high-quality studies confirmed the relevant impact of doxofylline on FEV1 (MD 239 ml, 95%CI 167–311; I² 0%; P < 0.001 vs. control) (Fig. 2C).

The overall analysis of the safety profile showed that the administration of doxofylline in COPD patients induced a significant (P < 0.001) but moderate increase of AEs frequency (Pr 0.03, 95%CI 0.02–0.04; I² 88%) (Fig. 3). However, the subset and pooled analysis showed that among the specific AEs reported in the studies, only the frequencies of epigastria, nausea, dyspepsia and headache were significantly (P < 0.05) increased in patients receiving doxofylline (Fig. 4, Table 1). Overall, 2.24% patients withdrew from the studies due to AEs.

3.2.2. Secondary endpoints

Doxofylline elicited also a beneficial impact on secondary endpoints. A significant proportion (P < 0.001) of patients treated with doxofylline achieved a high level of therapeutic efficacy (Pr 0.82, 95%CI 0.77–0.87; I² 30%), and the daily use of rescue medication significantly (P < 0.001) decreased more than three folds during the treatment (PLN -1.15, 95%CI -1.76 to −0.54; I² 98%). The overall improvement of dyspnea score induced by doxofylline was greater than one point (MD -1.03, 95%CI -1.09 to −0.97 I² 0%; P < 0.001 compared with control).

3.3. Risk of bias and evidence profile

A substantial and significant (P < 0.001) level of heterogeneity resulted in this pairwise meta-analysis concerning the primary endpoints. The sensitivity analysis indicated that the main source of heterogeneity was related to the clinical trials of Cipri et al. [24], Di Vennanzio et al. [31], and Oreifice et al. [36] when the analysis was focused on the impact of doxofylline on FEV1, and with the studies of Cipri et al. [24] and Wu et al. [21] when it was focused on the frequency of AEs. In
fact, acceptable levels of heterogeneity were found for both the primary endpoints when these studies were excluded from the meta-analysis (FEV₁: I² = 42%, P = 0.06; AEs I² = 49%, P = 0.11).

Most the meta-analyzed clinical trials enrolled stable COPD patients, but one study enrolled specifically exacerbated COPD patients [21]. Considering that the study of Wu et al. [21] reported data on the safety profile of doxofylline but not on lung function, we assessed whether the clinical condition of COPD patients might represent a bias on the frequency of AEs. The sensitivity analysis indicated that no significant differences (P > 0.05) were found for the effects estimates on the proportion of AEs when exacerbated COPD patients were excluded from the meta-analysis.
No significant heterogeneity was found either for FEV\textsubscript{1} when high quality studies were meta-analyzed \((I^2 = 0, P = 0.42)\), or for the safety profile when the effect estimates of the specific AEIs were considered \((I^2 = 16, P = 0.19)\). Although a certain level of dispersion was detected by the visual analysis of funnel plot \((Fig. 5A and C)\), the lack of bias concerning the effect estimates of either the primary endpoints was confirmed by Egger’s test \((Fig. 5B and D)\).

The ethnicity, the level of bronchial reversibility, and the date of publication from the first clinical trial did not represent confounder variables that may have altered the FEV\textsubscript{1} effect estimates. A signal of confounding factor was detected for the Jadad score \((sub-group analysis: intravenous SMD 1.70, 95\%CI 0.67–0.31\) studies \(SMD 0.72, 95\%CI 0.31–1.13\)) and the route of administration \((sub-group analysis: intravenous SMD 1.70, 95\%CI 0.67–2.74; oral SMD 1.01, 95\%CI 0.63–1.39\)). The total dose of doxofylline administered to patients during the studies was a confounder variable for the FEV\textsubscript{1} effect estimates \((sub-group analysis: < 30 \text{g SMD 0.93, 95\%CI 0.62–1.24}; \geq 30 \text{g SMD 2.35, 95\%CI 1.51–3.19})\).

The ethnicity, the level of bronchial reversibility, the date of publication from the first clinical trial and the route of administration did not represent confounder covariates with regard to the effect estimates of AEs. On the other hand, both the Jadad score \((sub-group analysis: low quality studies Pr 0.35, 95\%CI 0.01–0.06; high quality studies Pr 0.07, 95\%CI 0.03–0.12)\) and the total dose of doxofylline \((sub-group analysis: < 30 \text{g Pr 0.07, 95\%CI 0.05–0.10}; \geq 30 \text{g Pr 0.004, 95\%CI 0.001–0.007})\) were confounder variables for the frequency of AEs.

More details on meta-regression analysis and the statistical significance of confounder variables with regard to FEV\textsubscript{1} and AEs are reported in the supplementary data file \((Figure S2)\).

The GRADE analysis indicated high quality of evidence \((+++++)\) for the impact of doxofylline on FEV\textsubscript{1} expressed as volume \((\text{ml})\), and moderate quality of evidence \((++++)\) for the safety profile of doxofylline administered in COPD patients \((Table 2)\). The GRADE analysis has been carried out in high quality RCTs \((Jadad score \geq 3)\), excluded for FEV\textsubscript{1} expressed as \% of predicted because only one high quality study \([40]\) reported this variable.

4. Discussion

The results of this pairwise meta-analysis confirm that doxofylline is effective and safe when administered to COPD patients. Compared to the control, doxofylline significantly improves lung function and dyspnea, and reduces the daily use of rescue medication more than the proposed minimal clinically important difference \((MCID)\) values for COPD outcomes \([42]\). Similarly to all xanthines, it induces some AEs, but they are mild in severity. In fact, although there was a numerically larger rate of AEs in patients treated with doxofylline than in control groups, the percentage of patients that withdrew from the clinical trials due to AEs was low, and the most frequently reported \((\geq 1\%)\) AEs in patients receiving doxofylline were epigastralgia, nausea, dyspepsia, headache and gastrointestinal discomfort.

It is of interest that while the overall analysis of the safety profile of doxofylline in COPD showed a high level of heterogeneity, the subset analysis of the specific AEs associated with the treatment provided no significant heterogeneity of the effect estimates. In any case, the quality of evidence on the safety profile was acceptable concerning both the total number of AEs and the patients that experienced at least one AE. The findings regarding the safety profile of doxofylline contrast with the evidence that the use of theophylline at conventional doses causes a high frequency of adverse effects \([43]\). It is likely that the decreased affinities towards adenosine A\(_1\) and A\(_2\) receptors of doxofylline may account for its better safety profile \([3]\).

It must be emphasized that doxofylline elicited a large to very large improvement in FEV\textsubscript{1}, inducing a mean improvement in FEV\textsubscript{1} of 317 ml compared to baseline values. Keeping focused exclusively on the high-quality studies, also in this case the average improvement in FEV\textsubscript{1} induced by doxofylline was large \((239 \text{ml})\). These values are considerably higher than those reported for theophylline in some meta-analyses \([44,45]\). Intriguingly, although the study of Mutti et al. \([34]\) provided a huge level of dispersion with regard to the change in FEV\textsubscript{1} reported in ml, probably because of the low number of enrolled patients, it did not influence either the heterogeneity or the quality of evidence when the analysis was performed on high quality RCTs.

The change in percentage of FEV\textsubscript{1} \((8.20\%\) increase) is weak when
Fig. 4. Subset analysis of the impact of doxofylline vs. control on the proportion of specific AEs reported in the studies included in this meta-analysis. AEs: adverse events.
compared with the change reported in ml. Such a discrepancy can be explained by considering that all the high quality RCTs expressed the changes in FEV₁ as volume and that the GRADE analysis provided a high quality of evidence for this outcome. Conversely, the studies that reported the impact of doxofylline on the percentage of change in FEV₁ were low quality studies that provided just low quality of evidence.

This meta-analysis has certainly some limitations that need to be highlighted. It has been impossible to evaluate the effect of doxofylline taking into account the severity of the disease and clinical condition of COPD patients, the presence of comorbidities, and use of concomitant medications. Furthermore, most clinical trials did not use a placebo as comparator. There was also a wide range of drug exposure between the studies analyzed, from hours to days or even months. In fact, the meta-regression analysis, a tool that permits to quantify the impact of moderator variables on study effect size [46], has shown that the total dose of doxofylline administered to patients during the studies has influenced the change in FEV₁. In any case, our analysis does not allow us to conclude that a longer-term treatment is better than a shorter-term treatment regimen or that higher doses are necessary for increased severity of the COPD. Nonetheless, the evidence generated by the meta-regression analysis that a longer treatment time leads to less AEs seems to be very interesting and maybe suggest that tolerance to AEs may be possible following chronic treatment with doxofylline.

The limitations of this study mainly stem from the lack of specific information in the papers that are being considered and, consequently, cannot be overcome by further analysis. Thus, the overall results of this quantitative synthesis should be interpreted with caution.

However we must point out that, when high quality RCTs were meta-analyzed, the quality of evidence was high for the impact of doxofylline on the change in FEV₁ expressed as volume (ml), and acceptable with regard to the influence of doxofylline on the frequency of AEs. The quality of the effect estimates resulting from the analysis of high quality RCTs was also confirmed by the visual analysis of funnel plot, a graphical method to check for the existence of publication bias, and supported by Egger’s test, which assesses whether the funnel plot is symmetrical by measuring the intercept from regression of standard

| AEs (n) | Frequency (%) | Rank | P     |
|--------|--------------|------|-------|
| Epigastralgia 21 | 4.28 | + + | *** |
| Dyspepsia 12 | 2.44 | + + | * |
| Headache 12 | 2.44 | + + | * |
| Nausea 9 | 1.63 | + + | *** |
| Gastrointestinal discomfort 5 | 1.02 | + | NS |
| Anorexia 3 | 0.61 | + | NS |
| Insomnia 3 | 0.61 | + | NS |
| Pulpsitation 3 | 0.61 | + | NS |
| Arrhythmia 2 | 0.41 | + | NS |
| Constipation 2 | 0.41 | + | NS |
| Dry mouth 2 | 0.41 | + | NS |
| Pain chest 2 | 0.41 | + | NS |
| Anxiety/irritability 1 | 0.20 | + | NS |
| Dizziness 1 | 0.20 | + | NS |
| Other CNS disturbances 1 | 0.20 | + | NS |
| Sweating 1 | 0.20 | + | NS |
| Tremors 1 | 0.20 | + | NS |
| Vomiting 1 | 0.20 | + | NS |

+ + : common (≥1/1,00 to < 1/10); + : uncommon (≥1/1000 to < 1/100); *P < 0.05 and ***P < 0.05, in agreement with the proportion of specific AEs reported in the studies included in this meta-analysis; AEs: adverse events; COPD: chronic obstructive pulmonary disease; EMA: European Medicine Agency; NS: not significant.

**Table 1**

Pooled analysis of AEs extracted from the studies on doxofylline in COPD patients and ranked by frequency in agreement with EMA guidelines [41].

**Fig. 5.** Funnel plot (left panels) and graphical representation of Egger’s test (right panels) for the overall impact of doxofylline vs. control on the changes in FEV₁ (A and B) and the frequency of AEs (C and D). AEs: adverse events; FEV₁: forced expiratory volume in 1 s; SE: standard error; SMD: standardized mean difference; SND: standard normal deviate.
normal deviates against precision [47].

5. Conclusions

Notwithstanding the above-mentioned limitations, this pairwise meta-analysis suggests that in patients with COPD doxofylline acts as a bronchodilator drug having a wider therapeutic window than theophylline. These characteristics, along with its well-described anti-inflammatory [48] and steroid sparing effects [49] suggest that when a xanthine is indicated [50], doxofylline should be considered as an alternative to theophylline in the treatment of patients with COPD.

Funding sources

ABC Farmaceutici that manufactures and sells medicinal products containing doxofylline funded LC for working on this manuscript.

Declaration of interest

MC and MGM are consultants at the ABC Farmaceutici and CP at Eurodrug that manufacture and sell medicinal products containing doxofylline. LC received compensation for working on this manuscript. PR has no competing interests.

Acknowledgements

None.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.pupt.2018.04.010.

Table 2

GRADE evidence profile: impact of doxofylline vs. control (placebo, untreated subjects, baseline values) on changes in FEV1 and frequency of AEs in COPD patients.

| Outcome | Quality assessment: impact of doxofylline in COPD | Quality |
|---------|-----------------------------------------------|---------|
| FEV1 (ml) from high quality RCTs | Not serious | Not serious | Not serious | Not serious |
| FEV1 (% predicted) from all RCTs | Seriousa | Seriousb | Not serious | Not serious |
| AEs (patients with at least one AE) from high quality RCTs | Not serious | Seriousb | Not serious | Not serious |
| AEs (reported AEs) from high quality RCTs | Not serious | Seriousb | Not serious | Not serious |

GRADE Working Group grades of evidence

High quality: we are very confident that the true effect lies close to that of the estimate of the effect.

Moderate quality: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low quality: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

5. Conclusions

Notwithstanding the above-mentioned limitations, this pairwise meta-analysis suggests that in patients with COPD doxofylline acts as a bronchodilator drug having a wider therapeutic window than theophylline. These characteristics, along with its well-described anti-inflammatory [48] and steroid sparing effects [49] suggest that when a xanthine is indicated [50], doxofylline should be considered as an alternative to theophylline in the treatment of patients with COPD.

Funding sources

ABC Farmaceutici that manufactures and sells medicinal products containing doxofylline funded LC for working on this manuscript.

Declaration of interest

MC and MGM are consultants at the ABC Farmaceutici and CP at Eurodrug that manufacture and sell medicinal products containing doxofylline. LC received compensation for working on this manuscript. PR has no competing interests.

Acknowledgements

None.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.pupt.2018.04.010.

References

[1] J.S. Franzone, R. Cirillo, D. Barone, Doxofylline and theophylline are xanthines with partly different mechanisms of action in animals, Drugs Exp. Clin. Res. 14 (1988) 487–489.
[2] C.P. Page, Doxofylline: a new xanthine, Pulm. Pharmacol. Ther. 23 (2010) 231–234.
[3] J. van Mastbergen, T. Jolaa, L. Allegra, C.P. Page, The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism, Pulm. Pharmacol. Ther. 25 (2012) 55–61.
[4] M.G. Matera, C. Page, M. Cazzola, Doxofylline is not just another theophylline!, Int. J. COPD 12 (2017) 3487–3493, http://dx.doi.org/10.2147/IJCPD.S150887.
[5] Y. Zhang, K. Zeng, J. Wang, H. Gao, Y. Nan, X. Zheng, Identifying the antiasthmatic target of doxofylline using immobilized β2-adrenoceptor based high-performance affinity chromatography and site-directed molecular docking, J. Mol. Recognit. 29 (2016) 492–498.
[6] D. Shukla, S. Chakraborty, S. Singh, B. Mishra, Doxofylline: a promising methyl xanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease, Expert Opin. Pharmacother. 10 (2009) 2343–2356.
[7] W.R. King, J. He, Understanding the role and methods of meta-analysis in IS research, Commun. Assoc. Inf. Syst. 16 (2005) 32.
[8] G. Pare, M.C. Trudel, M. Jaana, S. Kbins, Synthesizing information systems knowledge: a typology of literature reviews, Inf. Manag. 52 (2015) 183–199.
[9] T. Greco, A. Zangrillo, G. Biomdi-Zoccai, G. Landoni, Meta-analysis: pitfalls and hints, Heart Lung Vessel. 5 (2015) 219–225.
[10] J.H. Noble Jr., Meta-analytic methods, strengths, weaknesses, and political uses, J. Lab. Clin. Med. 147 (2006) 7–20.
[11] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, P. Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement, Open Med. 3 (2008) e123–e130.
[12] D. Moher, L. Shamseer, M. Clarke, D. Petticrew, E. Gheri, A. Liberati, M. Petticrew, et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement, Syst. Rev. 4 (2015) 1.
[13] L. Calzetta, P. Rogliani, M.G. Matera, M. Cazzola, A systematic review with meta-analysis of dual bronchodilution with LAMA/LABA for the treatment of stable COPD, Chest 149 (2016) 1181–1196.
[14] M. Cazzola, P. Rogliani, L. Calzetta, N.A. Hanania, M.G. Matera, Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis, COPD 14 (2017) 552–563.
[15] G. Guyatt, A.D. Oxman, E.A. Akl, R. Kunz, G. Vist, J. Brozek, et al., GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, J. Clin. Epidemiol. 64 (2011) 383–394.
[16] J.P. Guevara, J.A. Berlin, F.M. Wolf, Meta-analytic methods for pooling rates when follow-up duration varies: a case study, BMC Med. Res. Methodol. 4 (2004) 17.
[17] J.P.T. Higgins, S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011], (2011) Available from: www.cochrane-handbook.org The Cochrane Collaboration.
[18] R. Bosni, F. Berni, Double blind multicenter trial on efficacy and tolerability of doxofylline vs aminophylline in patients with chronic airway obstruction and reversible bronchospasm, Ital. J. Chest Dis. 43 (1989) 355–360.
[19] G. Melillo, G. Balzano, F. Jobide, A. De Felice, V. Campisi, M. Capone, et al., Treatment of reversible chronic obstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial, Int. J. Clin. Pharmacol. Res. 9 (1989) 396–405.
[20] C.K. Santra, Treatment of moderate chronic obstructive pulmonary disease (stable) with doxofylline compared with slow release theophylline-a multicentre trial, J. Indian Med. Assoc. 106 (2008) 791–792 4.
[21] S.-L. Wu, S.-Z. Wang, Observation of doxofylline in treatment of acute exacerbation chronic obstructive pulmonary disease, Med. J. West China (2011) 5 065.
[22] J.W. Liu, In vitro evaluation of doxofylline's effect on C57BL/6J, C3H/HeJ and CBA/H mouse lung tissue, Acta Pharmacol. Sin. 22 (2001) 79–82.
[23] T. Wang, G. Luo, Y. Hu, J. Ma, J. Wang, et al., Comparative study on the efficacy of tirofiban in the treatment of unstable angina, J. Huaxi Med. Sci. 31 (2011) 614–618.
[24] A. Cirpi, F. Pozzuz, F.L. Dini, Cardiac rhythm disturbances in patients with chronic obstructive pulmonary disease: effects of different methylxanthine drugs, Minerva Cardiol. 43 (1994) 268–278.
[25] O. Marino, E. Silvi, A. Lilli, C. Sinpiella, C. Montironi, G. Marino, et al., Studio comparativo tra doxofylline e trofiline anidra a rilascio prostrato in soggetti affetti da broncopneumopatia cronica ostruttiva, L’uomo e la Medicina 4 (1988) 33–37.
[26] J. Cohen, Statistical power analysis, Curr. Dir. Psychol. Sci. 1 (1992) 98–101.
[27] P. Rogliani, L. Calzetta, F. Cavalli, M.G. Matera, M. Cazzola, Pirfenidone, nintedanib and tacrolimus: a systematic review and meta-analysis, Pulm. Pharmacol. Ther. 40 (2016) 95–103.
[28] B.C. Wallace, I.J. Dahabreh, T.A. Trikalinos, J. Lau, P. Trow, C.H. Schmid, Closing the gap between methodologists and end-users: R as a computational back-end, J. Stat. Softw. 49 (2012) 1–15.

[29] F. Villani, P. De Maria, E. Ronchi, M. Galimberti, Oral doxophylline in patients with chronic obstructive pulmonary disease, Int. J. Clin. Pharmacol. Ther. 35 (1997) 107–111.

[30] F. De Benedetto, G. Fini, F.L. Dini, M. Fuciarelli, M. Sborgia, A. Del Ponte, Cardio-respiratory effects of intravenous infusion of xanthine derivatives: gas exchange and dynamic electrocardiogram monitoring in COPD patients, Ital. J. Chest Dis. 45 (1991) 353–357.

[31] U. Orfei, P.L. Struzzo, F.L. Dini, P. Biffignandi, A randomized placebo-controlled clinical trial to compare efficacy and safety of doxofylline and bamiphilline in COPD patients, Clinica e Terapia 2 (1991) 109–113.

[32] M. Gentile, V. Lo Giudice, R. Picarelli, F. Degiovanni, A. Del Ponte, Cardiovascular effects of intravenous infusion of xanthine derivatives: gas exchange and dynamic electrocardiogram monitoring in COPD patients, Ital. J. Chest Dis. 45 (1991) 353–357.

[33] D. Provvedi, M. Rubegni, P. Biffignandi, Pharmacokinetic interaction between doxofylline and digitalis in elderly patients with chronic obstructive bronchitis, Acta Ther. 16 (1990) 239–246.

[34] L. Mutti, B. Castagneto, L. Occhionero, M. Botta, D. Degiovanni, P. Budel, et al., Variations in aspecific bronchial reactivity elicited by methacholine in chronic bronchitis patients treated with doxofylline. Double blind cross-over study versus theophylline slow release, Acta Toxicologica et Therapeutica 12 (1991) 269–276.

[35] M. Giorgi, P.M. Sestini, P. Brucciale, C. Rosi, P. Michetti, M. Ruttili, Treatment with the xanthine derivative doxofylline in patients intolerant to theophylline (Abstract P1220), Eur. Respir. J. 8 (1993) 417.

[36] S. Di Venanzio, S. Mariotta, F. Mannino, O. Adani, M. Masullo, Doxophylline improves exercise tolerance in chronic obstructive pulmonary disease, Clinica e Terapia 3 (1992) 1–10.

[37] M. Dore, P. Biffignandi, M.H. Mitnick, F.S. Carauso, Doxofylline: long-term safety in COPD patients, Ann. Allergy 66 (1990) 95.

[38] P. Panaccio, F. Virili, A randomised clinical study comparing doxofylline and bamiphilline in chronic obstructive pulmonary disease, Int. J. Drugs Ther. 6 (1989) 1–4.

[39] D. Lal, S. Manocha, A. Ray, V.K. Vijayan, R. Kumar, Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease, J. Basic Clin. Physiol. Pharmacol. 26 (2015) 443–451.

[40] M.F. Akram, M. Nasiruddin, Z. Ahmad, R. Ali Khan, Doxofylline and theophylline: a comparative clinical study. Journal of clinical and diagnostic research, JCDR 6 (2012) 1681–1684.

[41] European Commission, A Guideline on Summary of Product Characteristics (SmPC), (2009) Available at: http://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf, Accessed date: 22 June 2017.

[42] Y.S. Punekar, S. Sharma, A. Pahwa, J. Takyar, I. Naya, P.W. Jones, Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis, Respir. Res. 18 (2017) 86.

[43] P.J. Barnes, Theophylline, Pharmaceutica1s (Basel) 3 (2010) 725–747.

[44] F.S. Ram, P.W. Jones, A.A. Castro, J.A. De Brito, A.N. Atallah, Y. Lacasse, et al., Oral theophylline for chronic obstructive pulmonary disease, Cochrane Database Syst. Rev. 4 (2002) CD003902.

[45] N.A. Molino, P. Zhang, A meta-analysis on the efficacy of oral theophylline in patients with stable COPD, Int. J. Chronic Obstr. Pulm. Dis. 1 (2006) 261–266.

[46] S.G. Thompson, J. Higgins, How should meta-regression analyses be undertaken and interpreted? Stat. Med. 21 (2002) 1559–1573.

[47] M. Egger, G.D. Smith, M. Schneider, C. Minder, Bias in meta-analysis detected by a simple, graphical test, BMJ 315 (1997) 629–634.

[48] Y. Riffq-Vasquez, F. Man, C.P. Page, Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse, Pulm. Pharmacol. Ther. 27 (2014) 170–178.

[49] Y. Riffq-Vasquez, R. Venkatasamy, C.P. Page, Steroid sparing effects of doxofylline, Pulm. Pharmacol. Ther. 48 (2018) 1–4.

[50] M. Cazzola, L. Calzetta, P.J. Barnes, G.J. Criner, F.J. Martinez, A. Papi, et al., Efficacy and safety profile of xanthines in COPD: a network meta-analysis, Eur. Respir. Rev. (2018), http://dx.doi.org/10.1183/16000617.00010-2018 Accepted.